For dual receptor agonists, trials provide measurable data on blood sugar control, weight loss, metabolic improvements, and potential side effects, guiding dosage and patient selection
Single vial tirzepatide (Zepbound) rollout Eli Lilly has launched single dose vials of tirzepatide (Zepbound) a dual GLP-1/GIP agonist approved for obesity and sleep apnea treatmentoffering a more accessible and flexible self-pay option
In addition to neuron ferroptosis at the lesion site, SCI causes motor cortex atrophy and functional changes early in the disease, and motor neuron death is thought to be the cause of primary motor cortex atrophy after SCI
Some research has found associations between oral berberine supplementation and changes in certain metabolic markers in specific study populations, particularly those with existing metabolic concerns
Elevated homocysteine levels have been linked to conditions such as heart attacks, strokes, and blood clots